Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcinoma: a systematic review and network meta-analysis
PurposeDiverse novel therapeutic options for hepatocellular carcinoma (HCC) have surfaced in recent years. However, it is increasingly difficult to select the optimal medication. This research aims to assess overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disea...
Saved in:
| Main Authors: | Wenjun Quan, Hanifah Fazlin Zulkifli, Norhafizah Saari, Rafidah Hanim Shueb, Nazri Mustaffa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1502931/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Circular RNAs in hepatitis B virus-induced hepatocellular carcinoma: A comprehensive review and recent advances
by: Wenjun Quan, et al.
Published: (2025-09-01) -
Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma
by: Wenjun Meng, et al.
Published: (2024-12-01) -
Adjuvant sorafenib for hepatocellular carcinoma after radiofrequency ablation versus radiofrequency ablation: analysis of its efficacy and safety
by: Wang Junxiao, et al.
Published: (2024-12-01) -
Roles and Mechanisms of Ferroptosis in Sorafenib Resistance for Hepatocellular Carcinoma
by: Liu R, et al.
Published: (2024-12-01) -
Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
by: Young Eun Chon, et al.
Published: (2025-01-01)